Table 1. Baseline characteristics of NSCLC patients according to EGFR-TKIs.
| Gefitinib | Erlotinib | Afatinib | P value | |
|---|---|---|---|---|
| N = 195 | N = 123 | N = 104 | ||
| Sex | 0.043 | |||
| Men | 59 (30.3) | 54 (43.9) | 39 (37.5) | |
| Women | 136 (69.7) | 69 (56.1) | 65 (62.5) | |
| Age (years) | 0.044 | |||
| <65 | 84 (43.1) | 68 (55.3) | 58 (55.8) | |
| >65 | 111 (56.9) | 55 (44.7) | 46 (44.2) | |
| Smoking | 0.446 | |||
| Never | 147 (75.4) | 92 (74.8) | 86 (82.7) | |
| Current or ever | 48 (24.6) | 31 (25.2) | 18 (17.3) | |
| BMI | 0.713 | |||
| <20 | 27 (13.8) | 21 (17.1) | 17 (16.3) | |
| >20 | 168 (86.2) | 102 (82.9) | 87 (83.7) | |
| EGFR mutation | 0.058 | |||
| Del19 | 87 (44.6) | 48 (39) | 58 (55.8) | |
| L858R | 94 (48.2) | 63 (51.2) | 23 (22.1) | |
| Clinical stage | 0.543 | |||
| IIIb | 9 (4.6) | 3 (2.4) | 3 (2.9) | |
| IV | 186 (95.4) | 120 (97.6) | 101 (97.1) | |
| ECOG PS | 0.332 | |||
| 0 & 1 | 164 (84.1) | 109 (88.6) | 93 (89.4) | |
| > 1 | 31 (15.9) | 14 (11.4) | 11 (10.6) | |
| Baseline brain metastasis | 0.360 | |||
| Absence | 161 (82.6) | 105 (86.1) | 82 (78.8) | |
| Presence | 34 (17.4) | 17 (13.9) | 22 (21.2) | |